Salk scientists identified new set of molecules that drive the growth of human pancreatic cancer cell lines, explaining how genetic mutations can activate genetic "super-enhancers" that promote out-of-control pancreatic cancer growth. They show the efficacy of an experimental drug that targets a super-enhancer related protein, demonstrating the promise of therapeutics that block the effects of super-enhancers.